NCT07034391View on ClinicalTrials.gov

A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 12, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2027

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

denosumab combined anti-PD-1 inhibitor with chemotherapy

120mg of denosumab，d1 in a 28-days cycle；200mg of anti-PD-1 inhibitor, d1 in a 21-days cycle；500mg/m2 of pemetrexed, d1 in a 21-days cycle; AUC4-5 of carboplatin, d1 in a 21-days cycle, for 4-6 cycle

Trial Locations (1)

110000

RECRUITING

The First Affiliated Hospital of China Medical University, Shenyang

All Listed Sponsors
lead

China Medical University, China

OTHER